GSK has appointed Emma Walmsley as its CEO designate. She will succeed Andrew Witty as GSK CEO when he retires on 31 March 2017. Emma is currently CEO of GSK Consumer Healthcare, established in 2015 following completion of GSK’s three-part transaction with Novartis. Prior to this, Emma was president of GSK Consumer Healthcare and has been a member of GSK’s Corporate Executive Team since 2011. Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as general manager, Consumer Products for L’Oreal China.
The Medicines Discovery Catapult (MDC) has appointed its first CEO. Chris Molloy, who has more than 25 years' experience in the international life science industry, will lead the MDC in developing new approaches for the discovery and early development of new medicines. Currently CEO at the RSA Group, Chris has significant senior level experience across pharmaceuticals, biotechnology, informatics and start-up sectors. He will join MDC in November and work with the MDC's Board to develop and implement the Catapult's initial five year business plan, which will be agreed with Innovate UK at the end of this year.
Ashfield, part of UDG Healthcare, has appointed Becky Paul as head of the commercial contact centre for the Ashfield Commercial business in the UK. Becky has successfully held a number of key roles in Ashfield since joining the company over seven years ago, and has now been appointed in a key leadership role in one of the fastest growing parts of the business. Becky will be responsible for operational delivery as well as inputting to overall strategy and development.
Novo Nordisk has announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016 and Lars Fruergaard Jørgensen (pictured) currently executive vice president and head of corporate development, will succeed him. Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in healthcare, economy and planning and over the years has completed overseas postings in the Netherlands, the US and Japan. Meanwhile, Jakob Riis, currently executive vice president and head of Region China, Pacific and Marketing, has been appointed executive vice president and head of North America operations.
Imperial College Health Partners (ICHP) has appointed a new managing director – Dr Axel Heitmueller, who is currently acting managing director of the Partnership. Axel will have a key role to play in North West London's health economy, working with the NHS, industry and other stakeholders to deliver transformational change. He has previously held senior positions in the NHS and government. He worked alongside Lord Ara Darzi to establish the ICHP and became its director of strategy in 2013.
Integrated Medhealth Communication (imc) has made two new appointments to its senior leadership team: Graeme Reay (pictured) joins the company as managing director of imc Global and Dr Azhar Rana joins as managing director of the company's first international hub, imc North America, located in Toronto. Graeme joins with 30 years of healthcare experience, most recently at Health Interactions where he was director of client services for Europe. Azhar practised general medicine in the UK before holding senior medical positions in pharma industry, including local and international roles at Bristol-Myers Squibb, Novo Nordisk and, most recently, AstraZeneca.
Verona Pharma has appointed Vikas Sinha to the Board as a non-executive director. Vikas has over 20 years of experience working in senior finance roles in the life science industry. He is currently executive VP and CFO of Alexion Pharmaceuticals, which he joined in 2005, where his responsibilities include global financial management. Prior to Alexion, Vikas spent 11 years at Bayer AG where he held various positions within the company in the US, Canada, Japan and Germany.
ClinTec International has appointed Rick Farris as executive VP of operations for North America. Rick joins from Novella Clinical, where he was VP in project management for the Biopharma and Rare Disease Business Unit. Previously, he was COO at Health Decisions, a CRO specialising in female reproductive health, rare disease and oncology.
Guillaume Clément (pictured) has been appointed executive VP, Region EUROPE+, at LEO Pharma, having most recently been VP, Area France, Canada and Belgium. Patrice Baudry has also been appointed as senior VP of global strategy and portfolio management, a new global function that includes strategy, business development and commercial strategy.
Louise Houson has joined MSD as managing director for the UK & Ireland. She previously headed MSD's Human Health business in Ireland, where she spent the past year overseeing a period of significant growth. She brings over 18 years' experience at MSD, having excelled in a series of roles in the UK business, including most recently leadership of the Specialty Care Business Unit. The new appointment sees Louise succeed Mike Nally, who will become the president of the global vaccines business for Merck & Co (as MSD is known in the US and Canada). Mike had served as the UK's managing director since 1 January 2014 - part of an overall 14-year tenure with the global healthcare company.
Dr Laura Ciccolini has joined Bedrock as commercial director. With over 15 years’ experience in life sciences and biochemical engineering Laura brings a track record of business start-up, development and management across functions in SMEs and large corporations, working closely with executive teams to plan and execute operational and strategic business goals. With experience in leading business strategy, marketing plans and their execution, over the past 15 years Laura has developed offerings and built the right teams and infrastructure, to deliver high quality services at a global level.